Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database

Myelodysplastic syndromes

Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies

Br J Haematol

Savic A, Taylor A, Fenaux P, Symeonidis A, Cargo C, Mittelman M, Petzer V, Sanz G, Čermák J, Langemeijer S, Hellström-Lindberg E, Comont T, D'Aveni M, Culligan D, Kotsianidis I, Panagiotidis P, van Marrewijk C, Smith A, Crouch S, de Witte T, Malcovati L, EUMDS registry

doi: 10.1111/bjh.70384

Genitourinary Cancer

Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis

Cancers (Basel)

Petermichl V, Fuchs S, Weber M, Gobat K, Micheloud C, Graf L, Gerth Y, Goede JS, Lehmann T, Driessen C, Mey UJM, Cathomas R, Cogliatti S, Silzle T

doi: 10.3390/cancers17162658

Myelodysplastic syndromes

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study

J Clin Oncol

Sallman DA, Garcia-Manero G, Daver N, Abboud CN, Stein E, Larkin K, Halpern AB, McCurdy SR, Al Malki MM, Subramanian Guru Murthy G, Silverman LR, Larson RA, Greenberg P, Gojo I, Wrobel T, Platzbecker U, Forsyth C, Vachhani P, Dong M, Shao J, Johnson LDS, Tan A, Lee C, Doshi P, Vyas P, Wei AH

doi: 10.1200/JCO-25-00617

Myelodysplastic syndromes

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study

Haematologica

Sekeres MA, Zeidan AM, Santini V, Komrokji RS, Fenaux P, Savona MR, Madanat YF, Valcárcel D, Regnault A, Creel K, Sun L, Wan Y, Navada S, Berry T, Feller F, Platzbecker U, Díez-Campelo M, Oliva EN

doi: 10.3324/haematol.2025.288956

Further Publications

Real-World Risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia and Other Second Primary Malignancies in Patients with Epithelial Ovarian Cancer Treated with Niraparib Maintenance Therapy: Results from a Postauthorization Safety Study

Adv Ther

van der Vorst MJDL, Maximiano Alonso C, Calderón Boyle TA, Schilder JM, Malinowska IA, Ye G, Kroep JR, Mañé Martínez JM, Kuplast J, Perhanidis J, Evans C, Golembesky AK, Tasca G, Kommoss S

doi: 10.1007/s12325-026-03600-9

Sarcoma

Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium

Eur J Cancer

Baldi GG, Giani C, Ljevar S, Denu RA, Napolitano A, Han I, Brunello A, Bhadri V, Sebio A, Andelkovic V, Campos F, Scanferla R, Abreu MH, Desar IME, Ogura K, Wong DD, Bae S, Bakhshi S, Lefler DS, Marquina G, Mazzocca A, Nakazawa MS, Thway K, Kim HS, Chiusole B, Connolly EA, Terés R, Antonescu C, Bellan E, V M G Bovée J, Davis JL, P Dei Tos A, Di Blasi E, Lazar AJ, Sbaraglia M, Schaefer IM, Taverna S, Gronchi A, Miceli R, Chen TW, Stacchiotti S

doi: 10.1016/j.ejca.2026.116666

Leukemia

Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms

Haematologica

Baccelli F, Merli P, Pigazzi M, Buldini B, Becilli M, Girardi K, Paganelli V, Pagano G, Leardini D, Muratore E, Vendemini F, Beneduce G, Tumino M, Saglio F, Sieni E, Mastrodicasa E, Maffeis M, Tambaro FP, Masetti R, Locatelli F

doi: 10.3324/haematol.2026.300775

Genitourinary Cancer

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis

Prostate Cancer Prostatic Dis

Saporita I, Calabrese M, Carfi FM, Mogavero A, Puglisi M, Treglia G, Vogl UM, Gillessen S, Pereira Mestre R, Pedrani M, Pecoraro G, Salfi G, Erhart CC, Lin HM, Tortola L, Di Maio M, Tucci M, Buttigliero C, Turco F

doi: 10.1038/s41391-026-01077-9

Multiple Myeloma (MM)

Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant

Br J Haematol

Venkatesh P, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, Giri S, Godby KN, Silbermann RW, Mikhail FM, Huls F, Reddy V, Costa LJ, Bal S

doi: 10.1111/bjh.70359

Related content

Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies

Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study

Real-World Risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia and Other Second Primary Malignancies in Patients with Epithelial Ovarian Cancer Treated with Niraparib Maintenance Therapy: Results from a Postauthorization Safety Study

Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium

Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis

Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant